Trial Profile

Prospective study of AADC gene therapy (AAV-hAADC gene therapy) in patients with aromatic L-amino acid decarboxylase (AADC) deficiency

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Nov 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eladocagene exuparvovec (Primary)
Indications Aromatic amino acid decarboxylase deficiency
Focus Therapeutic Use

Most Recent Events

29 Jun 2016 According to an Agilis Biotherapeutics media release, the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Agilis' gene therapy product candidate, AGIL-AADC, being developed for the treatment of Aromatic L-amino Acid Decarboxylase (AADC) deficiency.
29 Jun 2016 Results published in an Agilis Biotherapeutics media release.
02 Mar 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com